{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"CR measured by decrease in serum IgM levels to normal range, disappearnace of monoclonal protein by immunofixation, no evidence of bone marrow involvement, and resolution of any extramedullary disease by CT scan.","groups":[{"description":"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.\n\n\\-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression.\n\nGS-1101","id":"OG000","title":"GS-1101"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Participants were followed for the duration of therapy, a median of one cycle, for up to 3 cycles.","title":"Rate of Complete Response (CR)","type":"SECONDARY","unitOfMeasure":"percentage of participants with CR"}